Key points are not available for this paper at this time.
Background: Thyroid cancer is considered to exist among most common cancers and at the same time it is the most recurrent malignancy of the endocrine system. The most frequent type of thyroid cancer is papillary thyroid cancer (PTC), which contributes more than 80% globally 5 to 20 folds and miRNA-181b; 4-60 folds were observed in PTC in comparison to MNG and healthy tissue specimens. Conclusion: The boosted gene expression of the miRNA genes miRNA-146b and miRNA-181b manifests the plausible misregulations in deployment of these molecular musketeers as foes in PTC. This forged maladaptation of the miRNA-146b and miRNA-181b in the cancer microenvironment may warrant analytically, therapeutically and genetically surmountable miRNA targets for PTC clinical management prevention.
Khan et al. (Wed,) studied this question.